Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by garygpon Oct 23, 2024 12:45pm
161 Views
Post# 36278781

RE:AGM @ 10AM of Today EST

RE:AGM @ 10AM of Today ESTSo G1945V, what you have posted pretty much ties in with what goldtech feels and posts frequently; no news, no known plans at least nothing was disclosed in this regard, no update on cohort #5 which was a direct question posed by you, what the he!!. 

Goldtech has been spot on all along.  It seems abundantly clear, management runs PMN as they wish, almost like a private entity and doesn't give a tinkers damn about shareholders and possibly about the company either.  If they did,  why is the stock trading where it is and how long until the Nasdaq come looking for more explanations on where the stock trades and what if any plans are in the works to rectify this issue again.

Something that keeps me awake at night is if we should ever enter into any negotiations of any kind to partner or sell the company, who will be able to complete this task? certainly nobody within this organization.

How many ways ways are we screwed as shareholders?  Let me count the ways.
<< Previous
Bullboard Posts
Next >>